|
Report No. : |
340877 |
|
Report Date : |
12.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
BIONTECH AG |
|
|
|
|
Registered Office : |
An der Goldgrube 12 D 55131 Mainz |
|
|
|
|
Country : |
Germany |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
02.06.2008 |
|
|
|
|
Com. Reg. No.: |
HRB 41865 |
|
|
|
|
Legal Form : |
Public limited company |
|
|
|
|
Line of Business : |
Other
research and experimental development on natural sciences and engineering. |
|
|
|
|
No. of Employees : |
5 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made on
e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Germany |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GERMANY - ECONOMIC OVERVIEW
The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and declining net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms. Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong growth and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II - and its decrease to 5.2% in 2014. The new German government introduced a minimum wage of about $11.60 (8.50 euros) per hour to take effect in 2015. Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's total budget deficit - including federal, state, and municipal - to 4.1% in 2010, but slower spending and higher tax revenues reduced the deficit to 0.8% in 2011 and in 2012 Germany reached a budget surplus of 0.1%. The budget was essentially in balance in 2014. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016 though the target was already reached in 2012. The German economy suffers from low levels of investment, and a government plan to invest 15 billion euros 2016-18, largely in infrastructure, is intended to spur needed private investment. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela MERKEL announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany plans to replace nuclear power with renewable energy, which accounted for 27.8% of gross electricity consumption in 2014, up from 9% in 2000. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its electricity generating capacity and 46% of its base-load electricity production. Extremely low inflation, caused largely by low global energy prices and a weak euro, are expected to boost German GDP growth in 2015.
|
Source
: CIA |
BIONTECH
AG
Company Status: active
An der Goldgrube 12
D 55131 Mainz
Telephone:06131/90840
Telefax: 06131/908439
Homepage: www.biontech.de
E-mail: info@biontech.de
VAT
no.: DE263382495
Business relations are permissible.
LEGAL FORM Public
limited company
Date of foundation: 02.06.2008
Registered
on: 16.02.2009
Commercial Register: Local court 55116 Mainz
under: HRB
41865
EUR
181,660.00
Member of the Board of Directors:
Prof. Dr. Ugur Sahin
D 55131 Mainz
having sole power of
representation
born: 19.09.1965
Profession: University
professor
Marital status: unknown
Member of the Board of Directors:
Sean de Gruchy
Marett
GB Idar-Oberstein
having sole power of
representation
born: 16.01.1965
Profession: biochemist
Nationality: British
Marital status: unknown
Member of the Board of Directors:
Dr. Sierk Poetting
D 80331 München
having sole power of
representation
born: 19.01.1973
Marital status: unknown
Member of the Supervisory Board:
Prof. Dr. Christoph Huber
Am Stiftswingert 16
D 55131 Mainz
born: 14.02.1944
Profession: University
professor
Marital status: unknown
Member of the Supervisory Board:
Helmut Jeggle
D 55131 Mainz
Profession: Fully qualified
management
expert
Marital status: unknown
Member of the Supervisory Board:
Michael Motschmann
D 55131 Mainz
Profession: Fully
qualified merchant
Marital status: unknown
Further functions/participations of Prof. Dr.
Ugur Sahin (Member
of the Board of Directors)
Shareholder:
Medine GmbH
Philipp-von-Zabern-Platz
1
D 55116 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Registered
on: 01.12.2008
Reg. data: 55116 Mainz, HRB 41733
Shareholder:
TRON - Translationale
Onkologie an der
Universitätsmedizin der
Johannes
Gutenberg-Universität
Mainz gemeinnützige
GmbH
Freiligrathstr. 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR
40,000.00
Share: EUR 8,500.00
Registered
on: 28.02.2011
Reg. data: 55116 Mainz, HRB 43191
Manager:
Medine GmbH
Philipp-von-Zabern-Platz
1
D 55116 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 01.12.2008
Reg. data: 55116 Mainz, HRB 41733
Manager:
BioNTech Cell & Gene
Therapies GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private limited company
Share capital: EUR 26,453.00
Registered
on: 13.05.2009
Reg. data: 55116 Mainz, HRB 42024
Manager:
BioNTech Diagnostics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 23.04.2009
Reg. data: 55116 Mainz, HRB 41988
Manager:
BioNTech RNA
Pharmaceuticals GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 14.05.2009
Reg. data: 55116 Mainz, HRB 42030
Manager:
BioNTech Protein
Therapeutics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 02.06.2009
Reg. data: 55116 Mainz, HRB 42062
Manager:
TRON - Translationale
Onkologie an der
Universitätsmedizin der Johannes
Gutenberg-Universität
Mainz gemeinnützige
GmbH
Freiligrathstr. 12
D 55131 Mainz
Legal form: Private limited
company
Share capital: EUR 40,000.00
Registered
on: 28.02.2011
Reg. data: 55116 Mainz, HRB 43191
Further functions/participations of Sean de
Gruchy Marett (Member
of the Board of Directors)
Manager:
Europäisches Institut für
Forschung und
Entwicklung von
Transplantationsstrategien
GmbH (EUFETS)
Vollmersbachstr. 66
D 55743 Idar-Oberstein
Legal form: Private
limited company
Share capital: EUR 1,016,913.00
Registered
on: 02.09.2009
Reg. data: 55543 Bad Kreuznach, HRB 20806
Manager:
JPT Peptide Technologies
GmbH
Volmerstr. 5
D 12489 Berlin
Legal form: Private limited
company
Share capital: EUR 25,000.00
Registered
on: 11.05.2004
Reg. data: 14057 Berlin, HRB 92692 B
Further functions/participations of Dr. Sierk
Poetting (Member of
the Board of Directors)
Manager:
BioNTech Diagnostics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 23.04.2009
Reg. data: 55116 Mainz, HRB 41988
Manager:
BioNTech Cell & Gene Therapies GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 26,453.00
Registered
on: 13.05.2009
Reg. data: 55116 Mainz, HRB 42024
Manager:
BioNTech RNA
Pharmaceuticals GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 14.05.2009
Reg. data: 55116 Mainz, HRB 42030
Manager:
BioNTech Protein
Therapeutics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 02.06.2009
Reg. data: 55116 Mainz, HRB 42062
02.06.2008 - 11.12.2008 Petersberg 91. V V AG
Kurt-Schumacher-Str. 18-20
D 53113 Bonn
Public limited
company
11.12.2008 - 15.02.2009 BioNTech AG
Kurt-Schumacher-Str.
18-20
D 53113 Bonn
Public limited
company
16.02.2009 - 27.07.2010 BioNTech AG
Philipp-von-Zabern-Platz 1
D 55116 Mainz
Public limited
company
27.07.2010 - 05.03.2014 BioNTech AG
Hölderlinstr. 8
D 55131 Mainz
Public limited
company
17.03.2010 - 24.06.2015 Member of the Board of Directors
Michael
Maximilian Kring
D 80337 München
Main industrial sector
7219
Other research and experimental development on natural
sciences and engineering
Shareholder:
Europäisches Institut für
Forschung und
Entwicklung von
Transplantationsstrategien
GmbH (EUFETS)
Vollmersbachstr. 66
D 55743 Idar-Oberstein
Legal form: Private
limited company
Company Status: active
Share capital: EUR 1,016,913.00
Share: EUR 1,016,913.00
Reg. data: 02.09.2009
Local court
55543 Bad Kreuznach
HRB 20806
Shareholder:
BioNTech Diagnostics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Company Status: active
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Reg. data: 23.04.2009
Local court
55116 Mainz
HRB 41988
Shareholder:
BioNTech RNA
Pharmaceuticals GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Company Status: active
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Reg. data: 14.05.2009
Local court
55116 Mainz
HRB 42030
Shareholder:
BioNTech Cell & Gene
Therapies GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Company Status: active
Share capital: EUR 26,453.00
Share: EUR 25,000.00
Reg. data: 13.05.2009
Local court
55116 Mainz
HRB 42024
Shareholder:
BioNTech Protein
Therapeutics GmbH
An der Goldgrube 12
D 55131 Mainz
Legal form: Private
limited company
Company Status: active
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Reg. data: 02.06.2009
Local court
55116 Mainz
HRB 42062
Payment experience: within periods customary in this trade
Negative information:We have no negative
information at hand.
Balance sheet year: 2013
Type of ownership: Tenant
Address An der Goldgrube 12
D 55131 Mainz
Land
register documents were not available.
DEUTSCHE BANK, 55020 MAINZ A RHEIN
Sort. code: 55070040
BIC: DEUTDE5MXXX
Ac/ts receivable: EUR 13,827,205.00
Liabilities: EUR 20,548,737.00
Total numbers of vehicles: 1
-
Passenger cars:
1
Employees:
5
Balance
sheet ratios 01.01.2013 - 31.12.2013
Equity ratio [%]: 43.78
Liquidity ratio: 0.89
Return on total capital [%]: -61.57
Balance sheet ratios 01.01.2012 - 31.12.2012
Equity ratio [%]: 30.12
Liquidity ratio: 0.55
Return on total capital [%]: -55.94
Balance sheet ratios 01.01.2011 - 31.12.2011
Equity ratio [%]: 62.91
Liquidity ratio: 3.34
Return on total capital [%]: -39.63
Balance
sheet ratios 01.01.2010 - 31.12.2010
Equity ratio [%]: 78.09
Liquidity ratio: 1.67
Return on total capital [%]: -51.36
Equity ratio
The
equity ratio indicates the portion of the equity as compared
to
the total capital. The higher the equity ratio, the better the
economic stability (solvency) and thus the
financial autonomy of
a
company.
Liquidity ratio
The
liquidity ratio shows the proportion between adjusted
receivables
and net liabilities. The higher the ratio, the lower
the
company's financial dependancy from external creditors.
Return on total capital
The
return on total capital shows the efficiency and return on
the
total capital employed in the company. The higher the return
on
total capital, the more economically does the company work
with the invested capital.
Type of balance
sheet: Company balance sheet
Origin of the present
balance sheet: electronic German Federal Gazette
Financial year: 01.01.2013 - 31.12.2013
ASSETS EUR 45,593,576.93
Fixed assets
EUR 26,719,746.19
Intangible assets
EUR 6,005,701.54
Tangible
assets EUR 1,773,412.53
Financial assets
EUR 18,940,632.12
Other / unspecified financial assets EUR 18,940,632.12
Current assets
EUR 18,848,304.12
Stocks
EUR 11,317.18
Accounts receivable
EUR 13,827,205.25
Liquid means
EUR 5,009,781.69
Remaining other assets
EUR 25,526.62
Accruals (assets)
EUR 25,526.62
LIABILITIES EUR 45,593,576.93
Shareholders' equity
EUR 21,649,542.78
Capital EUR 169,036.00
Subscribed capital (share capital)
EUR 169,036.00
Reserves
EUR 98,635,475.00
Capital reserves
EUR 98,635,475.00
Balance sheet profit/loss (+/-)
EUR -77,154,968.22
Balance sheet profit / loss
EUR -77,154,968.22
Provisions
EUR 1,182,181.67
Liabilities
EUR 20,548,736.92
Other liabilities
EUR 2,213,115.56
Deferrals (liabilities)
EUR 2,213,115.56
Type of balance
sheet: Company balance sheet
Origin of the present
balance sheet: electronic German Federal Gazette
Financial year: 01.01.2012 - 31.12.2012
ASSETS EUR 33,033,967.31
Fixed assets
EUR 20,979,436.87
Intangible assets
EUR 3,374,645.54
Tangible assets
EUR 339,158.21
Financial assets
EUR 17,265,633.12
Other / unspecified financial assets EUR 17,265,633.12
Current assets
EUR 12,044,910.47
Accounts receivable
EUR 10,655,606.39
Liquid means
EUR 1,389,304.08
Remaining other assets
EUR 9,619.97
Accruals (assets)
EUR 9,619.97
LIABILITIES EUR 33,033,967.31
Shareholders' equity
EUR 11,128,139.10
Capital
EUR 169,036.00
Subscribed capital (share capital)
EUR 169,036.00
Reserves
EUR 61,889,708.00
Capital reserves
EUR 61,889,708.00
Balance sheet profit/loss (+/-)
EUR -50,930,604.90
Balance sheet profit / loss
EUR -50,930,604.90
Provisions
EUR 683,662.89
Liabilities
EUR 20,843,593.32
Other liabilities
EUR 378,572.00
Deferrals
(liabilities) EUR 378,572.00
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.39 |
|
|
1 |
Rs.102.59 |
|
Euro |
1 |
Rs.74.90 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.